Related Experiment Video
Updated: Jul 8, 2025
A Quantitative Detection Method for MicroRNAs in the Kidney of an Ischemic Kidney Injury Mouse Model
Published on: September 11, 2020
Advances in the study of miRNAs in chronic kidney disease with cardiovascular complications
1Department of Geriatrics, Jiangyin Hospital of Traditional Chinese Medicine, Wuxi, Jiangsu, China.
Insights
MicroRNAs (miRNAs) show promise as early biomarkers for chronic kidney disease (CKD) and its cardiovascular complications. These stable molecules could improve diagnosis, prognosis, and treatment strategies for CKD patients.
Area of Science:
- Nephrology and Cardiovascular Medicine
- Molecular Biology and Genetics
Background:
- Chronic kidney disease (CKD) is a progressive condition leading to significant cardiovascular disease (CVD) morbidity and mortality.
- Current diagnostic and prognostic tools for CKD complications lack reliability, necessitating the search for novel biomarkers.
- MicroRNAs (miRNAs) are stable molecules in blood with potential roles in CKD pathogenesis and as diagnostic/prognostic markers.
Purpose of the Study:
- To explore the potential of miRNAs as early, non-invasive biomarkers for chronic kidney disease (CKD) and associated cardiovascular disease (CVD).
- To review the role of miRNAs in key CKD/CVD complications like vascular calcification and ventricular hypertrophy.
- To assess the therapeutic potential of miRNAs in managing CKD and its cardiovascular sequelae.
Main Methods:
- Literature review and synthesis of existing research on miRNAs in CKD and CVD.
- Analysis of studies investigating specific miRNAs (e.g., miR-30, miR-212, miR-133, miR-126, miR-92a-3p) in relation to CKD progression and vascular complications.
- Evaluation of the diagnostic, prognostic, and therapeutic implications of identified miRNA biomarkers.
Main Results:
- Numerous miRNAs are implicated in the progression of vascular calcification and ventricular hypertrophy in CKD.
- Specific miRNAs regulate critical endothelial functions, including angiogenesis and repair.
- Several non-invasive miRNA biomarkers have been identified with potential for enhanced CKD/CVD diagnosis and prognosis.
Conclusions:
- MicroRNAs represent promising biomarkers for early detection, risk stratification, and monitoring of CKD and its cardiovascular complications.
- Targeting specific miRNAs may offer novel therapeutic strategies for managing CKD-associated CVD.
- Further large-scale clinical validation is required to establish the definitive therapeutic utility of miRNAs in CKD management.
Abstract:
Chronic kidney disease (CKD) is characterised by gradual loss of renal function and cardiovascular disease (CVD) as its principal consequence. CVD is a substantial source of morbidity and death in the CKD population and a growing global concern. Because there are no reliable early biomarkers to follow the progression of CKD and predict the risk of complications, research into such molecules continues. Many studies have demonstrated that miRNAs are potentially important variables in CKD, are very stable in blood, and may be employed as diagnostic and prognostic markers for various disorders. Vascular calcification (VC) is a cell-mediated process that necessitates genetic defects in the combined cardiovascular issues of CKD and may be modulated in part by miRNAs. Numerous miRNAs have been linked to the progression of vascular calcification. Many miRNAs have been discovered as being important in ventricular hypertrophy, including miRNA-30, miRNA-212, and miRNA-133. Endothelium miR-126, miR-92a-3p, and others are important regulators of angiogenesis, endothelium repair, and homeostasis. Several interesting non-invasive miRNA biomarkers in CKD/CVD have been found, with the potential to enhance diagnostic accuracy, predict prognosis, track disease progression, and serve as novel therapy targets. However, large-scale clinical studies are still needed to determine the therapeutic utility of miRNA.
More Related Videos
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
06:48Quantitative Real-Time Polymerase Chain Reaction Evaluation of MicroRNA Expression in Kidney and Serum of Mice with Age-Dependent Renal Impairment
Published on: April 29, 2022
Related Concept Videos
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:10Nephrons